High-dose thiotepa and melphalan with hemopoietic progenitor support following induction therapy with epirubicin-paclitaxel-containing regimens in metastatic breast cancer (MBC)

C. Bengala, I. Pazzagli, F. Innocenti, S. Donati, C. Favre, M. C. Menconi, F. Greco, R. Danesi, C. Orlandini, V. Guarneri, M. D. Tacca, P. F. Conte

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background: Preliminary data from phase III randomized studies have failed to show benefit of HDC given as consolidation after anthracycline and alkylating-based chemotherapy in metastatic breast cancer (MBC). Moderate activity of induction regimens and selection of chemoresistant clones are among the possible reasons for these disappointing results. We therefore have designed a phase II study where high-dose alkylating agents are given as consolidation after an induction treatment including the most active agents (epirubicin and paclitaxel) without alkylating agents. Patients and methods: Patients with MBC not previously treated with chemotherapy for metastatic disease were eligible. After six courses of epirubicin-paclitaxel±gemcitabine patients received a course of thiotepa 600 mg/m2 + melphalan 160 mg m2 with hemopoietic support. Pharmacokinetic parameters of thiotepa and melphalan were measured and related to treatment outcomes. The L-VEF of the patients was monitored before and after treatment. Results: Forty-eight patients have been treated. Before HDC 14 patients were in CR, and 34 in PR. A median of 6.92 × 106 (range 1.53-16.6) CD34+ cells/kg were reinfused after HDC. Median days (range) to neutrophils > 0.5 × 109/l and platelets > 20,000 × 109/l were 9.5 (9-33) and 10 days (9-32), respectively. Symptomatic CHF was observed in two patients (4.1%). Cmax and AUC of thiotepa showed a linear relationship with time to progression (TTP) and overall survival (OS): r2=0.6. After HDC the conversion rate from PR to CR was 44.1%. At five years progression-free and overall survival rates are 37.5% and 65%, respectively. A treatment-related death was observed. Conclusions: High-dose thiotepa and melphalan after an epirubicin-paclitaxel-containing treatment is feasible, devoid of significant cardiotoxicity and very active. Pharmacokinetic parameters of high-dose thiotepa might be linked to treatment outcome.

Original languageEnglish
Pages (from-to)69-74
Number of pages6
JournalAnnals of Oncology
Volume12
Issue number1
DOIs
Publication statusPublished - 2001

Fingerprint

Thiotepa
Epirubicin
Melphalan
Paclitaxel
Breast Neoplasms
Alkylating Agents
Therapeutics
Pharmacokinetics
Drug Therapy
Anthracyclines
Disease-Free Survival
Area Under Curve
Neutrophils
Blood Platelets
Survival Rate
Clone Cells
Survival

Keywords

  • High-dose chemotherapy
  • Metastatic breast cancer
  • Paclitaxel

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

High-dose thiotepa and melphalan with hemopoietic progenitor support following induction therapy with epirubicin-paclitaxel-containing regimens in metastatic breast cancer (MBC). / Bengala, C.; Pazzagli, I.; Innocenti, F.; Donati, S.; Favre, C.; Menconi, M. C.; Greco, F.; Danesi, R.; Orlandini, C.; Guarneri, V.; Tacca, M. D.; Conte, P. F.

In: Annals of Oncology, Vol. 12, No. 1, 2001, p. 69-74.

Research output: Contribution to journalArticle

Bengala, C. ; Pazzagli, I. ; Innocenti, F. ; Donati, S. ; Favre, C. ; Menconi, M. C. ; Greco, F. ; Danesi, R. ; Orlandini, C. ; Guarneri, V. ; Tacca, M. D. ; Conte, P. F. / High-dose thiotepa and melphalan with hemopoietic progenitor support following induction therapy with epirubicin-paclitaxel-containing regimens in metastatic breast cancer (MBC). In: Annals of Oncology. 2001 ; Vol. 12, No. 1. pp. 69-74.
@article{ebd0cfb10de84bc4ada818d4a9ab49fe,
title = "High-dose thiotepa and melphalan with hemopoietic progenitor support following induction therapy with epirubicin-paclitaxel-containing regimens in metastatic breast cancer (MBC)",
abstract = "Background: Preliminary data from phase III randomized studies have failed to show benefit of HDC given as consolidation after anthracycline and alkylating-based chemotherapy in metastatic breast cancer (MBC). Moderate activity of induction regimens and selection of chemoresistant clones are among the possible reasons for these disappointing results. We therefore have designed a phase II study where high-dose alkylating agents are given as consolidation after an induction treatment including the most active agents (epirubicin and paclitaxel) without alkylating agents. Patients and methods: Patients with MBC not previously treated with chemotherapy for metastatic disease were eligible. After six courses of epirubicin-paclitaxel±gemcitabine patients received a course of thiotepa 600 mg/m2 + melphalan 160 mg m2 with hemopoietic support. Pharmacokinetic parameters of thiotepa and melphalan were measured and related to treatment outcomes. The L-VEF of the patients was monitored before and after treatment. Results: Forty-eight patients have been treated. Before HDC 14 patients were in CR, and 34 in PR. A median of 6.92 × 106 (range 1.53-16.6) CD34+ cells/kg were reinfused after HDC. Median days (range) to neutrophils > 0.5 × 109/l and platelets > 20,000 × 109/l were 9.5 (9-33) and 10 days (9-32), respectively. Symptomatic CHF was observed in two patients (4.1{\%}). Cmax and AUC of thiotepa showed a linear relationship with time to progression (TTP) and overall survival (OS): r2=0.6. After HDC the conversion rate from PR to CR was 44.1{\%}. At five years progression-free and overall survival rates are 37.5{\%} and 65{\%}, respectively. A treatment-related death was observed. Conclusions: High-dose thiotepa and melphalan after an epirubicin-paclitaxel-containing treatment is feasible, devoid of significant cardiotoxicity and very active. Pharmacokinetic parameters of high-dose thiotepa might be linked to treatment outcome.",
keywords = "High-dose chemotherapy, Metastatic breast cancer, Paclitaxel",
author = "C. Bengala and I. Pazzagli and F. Innocenti and S. Donati and C. Favre and Menconi, {M. C.} and F. Greco and R. Danesi and C. Orlandini and V. Guarneri and Tacca, {M. D.} and Conte, {P. F.}",
year = "2001",
doi = "10.1023/A:1008302402687",
language = "English",
volume = "12",
pages = "69--74",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "1",

}

TY - JOUR

T1 - High-dose thiotepa and melphalan with hemopoietic progenitor support following induction therapy with epirubicin-paclitaxel-containing regimens in metastatic breast cancer (MBC)

AU - Bengala, C.

AU - Pazzagli, I.

AU - Innocenti, F.

AU - Donati, S.

AU - Favre, C.

AU - Menconi, M. C.

AU - Greco, F.

AU - Danesi, R.

AU - Orlandini, C.

AU - Guarneri, V.

AU - Tacca, M. D.

AU - Conte, P. F.

PY - 2001

Y1 - 2001

N2 - Background: Preliminary data from phase III randomized studies have failed to show benefit of HDC given as consolidation after anthracycline and alkylating-based chemotherapy in metastatic breast cancer (MBC). Moderate activity of induction regimens and selection of chemoresistant clones are among the possible reasons for these disappointing results. We therefore have designed a phase II study where high-dose alkylating agents are given as consolidation after an induction treatment including the most active agents (epirubicin and paclitaxel) without alkylating agents. Patients and methods: Patients with MBC not previously treated with chemotherapy for metastatic disease were eligible. After six courses of epirubicin-paclitaxel±gemcitabine patients received a course of thiotepa 600 mg/m2 + melphalan 160 mg m2 with hemopoietic support. Pharmacokinetic parameters of thiotepa and melphalan were measured and related to treatment outcomes. The L-VEF of the patients was monitored before and after treatment. Results: Forty-eight patients have been treated. Before HDC 14 patients were in CR, and 34 in PR. A median of 6.92 × 106 (range 1.53-16.6) CD34+ cells/kg were reinfused after HDC. Median days (range) to neutrophils > 0.5 × 109/l and platelets > 20,000 × 109/l were 9.5 (9-33) and 10 days (9-32), respectively. Symptomatic CHF was observed in two patients (4.1%). Cmax and AUC of thiotepa showed a linear relationship with time to progression (TTP) and overall survival (OS): r2=0.6. After HDC the conversion rate from PR to CR was 44.1%. At five years progression-free and overall survival rates are 37.5% and 65%, respectively. A treatment-related death was observed. Conclusions: High-dose thiotepa and melphalan after an epirubicin-paclitaxel-containing treatment is feasible, devoid of significant cardiotoxicity and very active. Pharmacokinetic parameters of high-dose thiotepa might be linked to treatment outcome.

AB - Background: Preliminary data from phase III randomized studies have failed to show benefit of HDC given as consolidation after anthracycline and alkylating-based chemotherapy in metastatic breast cancer (MBC). Moderate activity of induction regimens and selection of chemoresistant clones are among the possible reasons for these disappointing results. We therefore have designed a phase II study where high-dose alkylating agents are given as consolidation after an induction treatment including the most active agents (epirubicin and paclitaxel) without alkylating agents. Patients and methods: Patients with MBC not previously treated with chemotherapy for metastatic disease were eligible. After six courses of epirubicin-paclitaxel±gemcitabine patients received a course of thiotepa 600 mg/m2 + melphalan 160 mg m2 with hemopoietic support. Pharmacokinetic parameters of thiotepa and melphalan were measured and related to treatment outcomes. The L-VEF of the patients was monitored before and after treatment. Results: Forty-eight patients have been treated. Before HDC 14 patients were in CR, and 34 in PR. A median of 6.92 × 106 (range 1.53-16.6) CD34+ cells/kg were reinfused after HDC. Median days (range) to neutrophils > 0.5 × 109/l and platelets > 20,000 × 109/l were 9.5 (9-33) and 10 days (9-32), respectively. Symptomatic CHF was observed in two patients (4.1%). Cmax and AUC of thiotepa showed a linear relationship with time to progression (TTP) and overall survival (OS): r2=0.6. After HDC the conversion rate from PR to CR was 44.1%. At five years progression-free and overall survival rates are 37.5% and 65%, respectively. A treatment-related death was observed. Conclusions: High-dose thiotepa and melphalan after an epirubicin-paclitaxel-containing treatment is feasible, devoid of significant cardiotoxicity and very active. Pharmacokinetic parameters of high-dose thiotepa might be linked to treatment outcome.

KW - High-dose chemotherapy

KW - Metastatic breast cancer

KW - Paclitaxel

UR - http://www.scopus.com/inward/record.url?scp=0035114663&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035114663&partnerID=8YFLogxK

U2 - 10.1023/A:1008302402687

DO - 10.1023/A:1008302402687

M3 - Article

VL - 12

SP - 69

EP - 74

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 1

ER -